Question

You have the following table of costs and benefits for alternative treatments Treatment # Cost Effectiveness...

You have the following table of costs and benefits for alternative treatments

Treatment #

Cost

Effectiveness (life years gained)

1

100000

5

2

200000

3

3

400000

10

4

500000

20

A.        Which treatment(s) if any, is strongly dominated?

B.        Which treatment(s) if any is weakly dominated?

C.        Calculate incremental cost effectiveness ratios.

D.        Assuming that a life year is considered to be worth up to 100000, which interventions would you choose, in the absence of budgetary constraints?

E.         How might budgetary constraints affect your decision on which interventions to choose?

0 0
Add a comment Improve this question Transcribed image text
Answer #1

A Treatment 1 is strongly dominated. Incremental cost per annum is 100000/5 = 20000 per year lowest of all other options.

B Treatment 2 is weakly dominated 200000/3 = 66,667 per year highest cost per year of all options.

C Incremental cost effectiveness ratios cannot be calculated here as potential savings/revenue increase is not provided.

D Option 4 as highest life means highest value. 20 years x 100000 = 20,00,000. Subtract 500000 from it you get 1500000. None of the other options will reach this level even in terms of revenue.  

E Since the lowest cost option is the most dominating one, budgetary considerations have no bearing on recommended option i.e. option 1.  

Add a comment
Know the answer?
Add Answer to:
You have the following table of costs and benefits for alternative treatments Treatment # Cost Effectiveness...
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for? Ask your own homework help question. Our experts will answer your question WITHIN MINUTES for Free.
Similar Homework Help Questions
  • The following information has been gathered on the costs and effectiveness of the two treatments, A and B. In this pro...

    The following information has been gathered on the costs and effectiveness of the two treatments, A and B. In this problem, costs and consequences are not discounted. Treatment A Treatment B Mortality rate 2% 5% Life expectancy for survivors 30 years 20 years Initial treatment cost $20,000 $10,000 Follow up costs, year 1 $5,000 $1,000 Annual follow up costs, all subsequent years $1,000 $500 Calculate the incremental cost and incremental benefit of the treatment alternatives. DC = DE = What...

  • The following information has been gathered on the costs and effectiveness of the two treatments, A...

    The following information has been gathered on the costs and effectiveness of the two treatments, A and B. In this problem, costs and consequences are not discounted. Treatment A Treatment B Mortality rate 2% 5% Life expectancy for survivors 30 years 20 years Initial treatment cost $20,000 $10,000 Follow up costs, year 1 $5,000 $1,000 Annual follow up costs, all subsequent years $1,000 $500 a. What is the total cost for the survivors receiving treatment A? $54,000 For decedents (assuming...

  • Which of the following describes cost-effectiveness analysis (CEA)? CEA compares the costs and benefits of a...

    Which of the following describes cost-effectiveness analysis (CEA)? CEA compares the costs and benefits of a specific treatment, such as a new drug. CEA results are presented in the form of a CEA ratio, where the numerator is the additional cost of the intervention and the denominator is some measure of the outcome of interest. CEA compares the additional costs of alternative approaches to achieve a specific outcome designed to improve health. b and c

  • FastBits Electronic Company Sdn. Bhd. is evaluating new precision inspection devices to help verify package quality....

    FastBits Electronic Company Sdn. Bhd. is evaluating new precision inspection devices to help verify package quality. The manager has obtained the following bids from four companies. All devices have a life of five years and minimum attractive rate of return of 6%. The alternatives are mutuallv exclusive DescriptionCompany A Company B Company C Company D Initial Cost (RM)420000 Annual Costs (RM) 900 Net Cash Flows (RM) 105000 IRR 100000 12000 28000 12 .4% 570000 23000 142500 79% 200000 9000 46000...

  • 1. Focusing on only the inpatient care cost (i.e., ignoring operating room costs), what is the...

    1. Focusing on only the inpatient care cost (i.e., ignoring operating room costs), what is the cost of a TAH (non-oncology) under each of the cost accounting systems? A tuboplasty? A TAH (oncology)? What accounts for the differences? Croswell University Hospital This report doesn't describe where our costs are generated. We're applying one standard to all patients, regardless of their level of care. What incentive is there to identify and account for the costs of each type of procedure? Unless...

  • what discuss can you make about medicalization and chronic disease and illness? Adult Lealth Nursing Ethics...

    what discuss can you make about medicalization and chronic disease and illness? Adult Lealth Nursing Ethics mie B. Butts OBJECTIVES After reading this chapter, the reader should be able to do the following: 1. Explore the concept of medicalization as it relates to the societal shift away from physician predominance of the 1970s. 2. Differentiate among the following terms: compliance, noncompliance, adherence, nonadherence, and concordance. 3. Examine cultural views with regard to self-determination, decision making, and American healthcare professionals' values...

  • What should have Merck & Co, Inc done differently in regards to river blindness? Merck &...

    What should have Merck & Co, Inc done differently in regards to river blindness? Merck & Company, Inc.: Having the Vision to Succeed by Stephanie Weiss and David Bollier An Expensive Care for a Poor Market In 1978, Dr. P. Roy Vagelos, then head of the Merck research labs, received a provocative memorandum from a senior researcher in parasitology, Dr. William C. Campbell. Dr. Campbell had made an intriguing observation while working with ivennectin, a new antiparasitic compound under investigation...

ADVERTISEMENT
Free Homework Help App
Download From Google Play
Scan Your Homework
to Get Instant Free Answers
Need Online Homework Help?
Ask a Question
Get Answers For Free
Most questions answered within 3 hours.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT